Prostate Cancer Treatment and Research

ProMPt: A modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilities

ProMPt is a syngeneic mouse platform modeling prostate cancer heterogeneity, revealing MYC's role in progression and showing that MAPK inhibition plus translation blockade synergistically suppresses castration-resistant tumors.

Disruption of NUAK2-Mediated RNA Splicing by Trilaciclib Reveals a Therapeutic Vulnerability in AR-Indifferent Prostate Cancer

This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.

NEUROG3 Is Sufficient to Drive Neuroendocrine Differentiation in Prostate Cancer Cells.

This study shows NEUROG3 can drive neuroendocrine differentiation in prostate cancer cells, identifying it as a potential mediator of cancer progression.

BUB1B MITOTIC KINASE DRIVES THERAPY RESISTANT PROSTATE CANCER

This study identifies BUB1B as a driver of castration-resistant prostate cancer and shows its role in enzalutamide resistance, suggesting it as a therapeutic target.

Targeting Endoplasmic Reticulum Stress and Nitroso-Redox Imbalance in Neuroendocrine Prostate Cancer: The Therapeutic Role of Nitric Oxide

This study identifies ER stress and nitroso-redox imbalance as key drivers of NEPC progression and shows that NO supplementation reduces tumor burden and metastasis in mice.

Genome-wide CRISPR screens identify PTGES3 as a novel AR modulator

This study uses CRISPR screens to identify PTGES3 as a novel modulator of AR protein levels and function in prostate cancer, showing its role in therapy resistance.

Thyroid Hormone Receptor Beta Signaling is a Targetable Driver of Prostate Cancer Growth

This study identifies TRβ as a driver of prostate cancer growth and shows that NH-3 inhibits PCa cell proliferation and tumor growth, particularly in castration-resistant models.

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

ECM-free patient-derived organoids preserve diverse prostate cancer lineages and uncover in vitro-enriched cell types

This study develops an ECM-free culture system for prostate cancer organoids, revealing diverse tumor lineages and identifying in vitro-enriched cell types through single-cell RNA sequencing.

CRlSPR/Cas9 screening revealed BlRC6-AS1/BlRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer

The paper identifies BIRC6-AS1/BIRC6 as a driver of abiraterone resistance in prostate cancer by stabilizing BIRC6 and promoting A20 degradation via NHEJ pathway disruption.

Targeting FOXA1 and FOXA2 Disrupts the Lineage-Specific Oncogenic Output Program in Prostate Cancer

This study shows that disrupting FOXA1 and FOXA2 disrupts oncogenic programs in both AR-positive and AR-negative prostate cancers.

A spatiotemporal atlas of orchiectomy-induced androgen deprivation-mediated modulation of cellular composition and gene expression in the mouse prostate.

This study maps the spatiotemporal changes in mouse prostate cellular composition and gene expression after orchiectomy-induced androgen deprivation, identifying new fibroblast subtypes and altered intercellular communication.

Association of HOXB13 G84E with prostate cancer among 592,158 men

This paper shows the HOXB13 p.G84E variant increases prostate cancer risk by threefold in men, but does not lead to more aggressive cancer.

Combination Treatment with NCX 4040 and Napabucasin Triggers Enhanced Oxidative Stress, STAT3 Inhibition and Plausible Immunogenic Activation in Metastatic Prostate Cancer Cells

This study shows that combining NCX 4040 and Napabucasin reduces prostate cancer cell viability, induces oxidative stress, inhibits STAT3, and activates immunogenic pathways.

Osthole Suppresses Prostate Cancer Progression by Modulating PRLR and the JAK2/STAT3 Signaling Axis

This study shows that Osthole inhibits prostate cancer by targeting PRLR and the JAK2/STAT3 pathway through in vitro and in vivo experiments.

ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis

This study identifies ECD as a novel androgen receptor target that promotes prostate cancer by enhancing glycolysis and oncogenic traits.

Cellular cartography reveals mouse prostate organization and determinants of castration resistance

This study maps the mouse prostate's cellular organization and identifies key determinants of castration resistance using single-cell and spatial transcriptomics.

TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer

This study identifies TRIM24 as a target for preventing prostate cancer progression by degrading it to counteract AR inhibition adaptation and tumor relapse.

Molecular switch mediates the glucocorticoid receptor transition from tumor suppressor to oncogene in the prostate

The paper identifies p63 as a molecular switch that determines the glucocorticoid receptor's role as a tumor suppressor or oncogene in prostate cancer.

Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate Cancer

The paper identifies a subgroup of mCRPC characterized by LINE1 repeat DNA elements flanking the AR gene, which drive AR overexpression and confer resistance to androgen signaling inhibitors.

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer

This paper identifies the EZH2-TTP-mTORC1 axis as a driver of phenotypic plasticity and therapeutic vulnerability in prostate cancer, showing that combined inhibition of EZH2 and PI3K/mTORC1 improves anti-tumor activity.

Dual pathway regulation of castration response and ferroptosis in the prostate epithelium

The paper shows that castration induces prostate epithelial regression via ferroptosis, mediated by two AR signaling pathways controlled by NKX3.1 and PTN.

Exploration of oncogenic cooperation between germline variation and somatic mutation in prostate cancer progression

This study identifies PTPRK as a gene modulated by TMPRSS2::ERG fusion and a regulatory SNP, showing its role in prostate cancer progression and potential as a biomarker.

YY1 relieves p300 autoinhibition to promote histone acetylation in advanced prostate cancer, enhancing the oncogenic signaling of Androgen Receptor Splice Variant 7

This study shows YY1 enhances p300 acetyltransferase activity in CRPC, promoting histone acetylation and oncogenic gene expression, and identifies a potential therapeutic target for overcoming drug resistance.

Androgen receptor-mediated assisted loading of the glucocorticoid receptor modulates transcriptional responses in prostate cancer cells

The paper shows that direct chromatin crosstalk between androgen receptor and glucocorticoid receptor in prostate cancer leads to distinct transcriptional responses associated with improved patient survival.

Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer

This study identifies NKX2-1-driven epigenetic and 3D chromatin remodeling as key to neuroendocrine prostate cancer progression and reveals CBP/p300 inhibitors as potential therapeutic targets.

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer

This study identifies SOX2 and FOXA1 as a transcriptional partnership driving proliferation and lineage plasticity in therapy-resistant prostate cancer.

Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling

The paper identifies PARP7 as an enzyme that ADP-ribosylates the androgen receptor, marking it for degradation and creating negative feedback on AR-dependent gene expression.

Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro

This study develops a ddPCR method to detect low-abundance TMPRSS2:ERG gene fusion transcripts in prostate cancer cells and evaluates potential initiators of these fusions.

TRIM33 loss reduces Androgen Receptor transcriptional output and H2BK120 ubiquitination

The paper shows TRIM33 enhances AR activity by reducing H2BK120 ubiquitination, without affecting AR protein stability.